Today: 7 February 2026
Subscribe
Browse Category

Biotech News 24 November 2025 - 7 December 2025

VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

Viking Therapeutics (NASDAQ: VKTX) has quietly become one of the most closely watched small-cap names in the weight-loss drug trade. As of the last trading session on Friday, December 5, 2025, VKTX closed at $38.55, giving the company a market capitalization of roughly $4.3–4.4 billion. Viking Therapeutics InvestorRoom+1 Yet Wall Street’s consensus 12‑month price targets sit in the high‑$80s to around $100 per share, implying 120–160% upside from current levels. StockAnalysis+2Ticker Nerd+2 A fresh December 7 analysis from German outlet boerse-global.de went further, calling out a “striking valuation gap” between the sub‑$40 share price and analyst targets that suggest the
7 December 2025
····
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Data and news current as of 7 December 2025. NVAX stock price now: where Novavax stands in December 2025 Novavax, Inc. (NASDAQ: NVAX) closed on Friday, 5 December 2025 at $6.91 per share, giving the vaccine maker a market value of around $1.1 billion.Novavax Investor Relations+1 Over the last year, NVAX has slipped roughly 20%, according to data from Investing.com and other market trackers.Investing.com+1 That’s modest compared with its longer-term collapse: Simply Wall St calculates that Novavax shares are down about 94% over the past five years, even after a flurry of recent milestones.Simply Wall St+1 Key trading stats as
7 December 2025
·····
Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Updated: December 6, 2025 Moderna, Inc. (NASDAQ: MRNA) has just had one of its most dramatic weeks of 2025. Shares plunged early in the week after news that the U.S. Food and Drug Administration (FDA) may tighten vaccine approval standards, then rebounded sharply on Friday after a massive French real‑world study reaffirmed the safety and effectiveness of its COVID‑19 vaccine. Investopedia+2Investopedia+2 As of the close on Friday, December 5, Moderna stock finished at $27.70, up 8.7% on the day and trading near the middle of its 52‑week range of $22.28 to $48.92, giving the company a market capitalization of about
6 December 2025
····
IonQ Stock (IONQ) on December 5, 2025: Quantum Breakthroughs, Biotech Deals, Big Money Flows and 2026 Forecast

IonQ Stock (IONQ) on December 5, 2025: Quantum Breakthroughs, Biotech Deals, Big Money Flows and 2026 Forecast

IonQ, Inc. (NYSE: IONQ) is back in the spotlight today after another burst of volatility that has pushed the stock to around the low‑$50s per share as of December 5, 2025. Different data sources show IONQ trading in the $51–55 range intraday, with notable pre‑market activity and heavy options volume. CoinCodex+1 That’s happening against a backdrop of: Below is a detailed, news‑driven IonQ stock analysis as of December 5, 2025, suitable for investors following the story on Google News and Discover. This is information, not investment advice – always do your own research or consult a licensed professional before making
5 December 2025
····
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025

Biomea Fusion, Inc. (NASDAQ: BMEA) is back in the spotlight after the company reported long‑term data showing that its experimental diabetes drug icovamenib (formerly BMF‑219) can deliver durable blood‑sugar control many months after patients stop taking it. The new results, presented at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles, pushed Biomea Fusion’s stock higher on Friday and have reignited debate over whether this beaten‑down biotech could still be a high‑risk turnaround story. Nasdaq+1 As of Friday, December 5, Biomea Fusion shares were trading in the low‑$1 range, giving the company a market
5 December 2025
····
Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Updated: December 4, 2025 Amgen Inc. (NASDAQ: AMGN) has quietly turned into one of 2025’s standout large‑cap healthcare winners. The biotech heavyweight is trading just below fresh 52‑week highs, powered by a clean sweep of earnings beats, a deepening obesity‑drug story around its MariTide program, and full FDA approval for its lung‑cancer therapy Imdelltra. At the same time, investors are grappling with tax and patent overhangs, looming drug price pressure and an increasingly crowded obesity market. Here’s a deep, Google‑News‑friendly dive into the latest Amgen stock news, forecasts and analysis as of December 4, 2025. Amgen stock today: price, performance
4 December 2025
····
Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Published: December 4, 2025 Key Takeaways Wall Street Re‑rates Regeneron After Big Run — and Bigger Dupixent Story Regeneron Pharmaceuticals has suddenly become one of the most hotly debated large‑cap biotechs on Wall Street. On Thursday, December 4, 2025, multiple analyst moves and fresh data reshaped the Regeneron (REGN) stock narrative: Taken together, these moves signal that, despite a sharp rally off the summer lows, many professionals still see upside in REGN stock, driven primarily by Dupixent, Regeneron’s blockbuster anti‑inflammatory drug co‑developed with Sanofi, and a deepening pipeline in genetics and oncology. Investing.com+1 At the same time, concerns about valuation
4 December 2025
·····
Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

As Tonix Pharmaceuticals transitions from clinical-stage hopeful to commercial biotech on the back of its new fibromyalgia drug Tonmya, Wall Street is split between blockbuster dreams and dilution fears. TNXP Stock on December 4, 2025: Price, Volume and Volatility Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) spent Thursday, December 4, 2025 trading around the high‑teens, with several data providers showing the stock near $19–20 per share during U.S. hours. MarketBeat cites a real‑time price of about $19.98, while CoinCodex shows $19.66, both up roughly 10–12% on the day. MarketBeat+1 That price puts Tonix’s market capitalization near $190 million, a tiny cap
4 December 2025
·····
AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge

AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge

New York — November 25, 2025 — Axsome Therapeutics (NASDAQ: AXSM) heads into Tuesday’s session trading just below fresh record highs, powered by blockbuster growth from its depression drug Auvelity, the launch of migraine pill Symbravo, and a rapidly expanding neuroscience pipeline. Shares closed on Monday, November 24, at $151.20, up 1.2% on the day and modestly higher in after-hours trading around $152. That puts AXSM near the top of its 52‑week range of $75.56 to $151.39, valuing the CNS-focused biotech at roughly $7.6 billion. StockAnalysis+1 Over the past year, Axsome’s stock has climbed more than 50% (around 54% on
25 November 2025
··
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics (NASDAQ: VKTX) heads into the Tuesday, November 25, 2025 session trading in the mid‑$30s, still digesting last week’s major milestone: the company has finished enrolling patients in its pivotal Phase 3 obesity trial VANQUISH‑1 ahead of schedule and above its original target. Viking Therapeutics InvestorRoom As of yesterday’s close (Monday, November 24), VKTX changed hands at $34.65, implying a market capitalization of roughly $3.9 billion. Stock Titan Shares sit well below their 52‑week high of $56.25, but far above the 52‑week low of $18.92, underscoring how volatile the weight‑loss drug trade has become. Investing.com+1 With Phase 3 trials
25 November 2025
····
BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

Published: November 24, 2025Ticker: Bristol Myers Squibb Company (NYSE: BMY) Key takeaways This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. BMY stock today: a 4% move that stands out Bristol Myers Squibb shares climbed sharply on Monday, with BMY changing hands around $48.24, up roughly $1.99 from Friday’s close near $46.25—a gain of about 4.3% on the day. Intraday, the stock traded between roughly $46.39 and $48.63, on volume in the low‑ to mid‑teens of millions of shares—broadly in line with recent average daily trading activity,
24 November 2025
····
BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen Inc. (NASDAQ: BIIB) shares surged to fresh 52‑week highs on Monday, November 24, 2025, as investors reacted to a high‑profile Alzheimer’s drug failure at Novo Nordisk and a new immunology partnership with Dayra Therapeutics. By the closing bell, BIIB stock finished at $177.42, up about 1.2% from Friday’s close of $175.30. The stock traded as high as $185.17 intraday, with volume just over 2.0 million shares, roughly in line with its recent average. StockAnalysis Over the last six months, Biogen has climbed roughly 40%, and about 11% over the past year, reflecting renewed confidence in its Alzheimer’s and neurology
24 November 2025
····
1 … 4 5 6 7 8 … 13

Stock Market Today

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

7 February 2026
BP shares closed up 1.9% at 478 pence Friday, just below a 52-week high, as the company continued buybacks ahead of next week’s results. BP repurchased 2.789 million shares on February 6. Oil prices firmed on geopolitical risk, with Brent at $68.05 a barrel, but sector outlook remains uncertain. Investors await BP’s earnings and dividend decision due Tuesday.
Go toTop